At the JP Morgan Conference 2025, CEO Chen said the potential of the Biosecure Act passing has had only a minimal chilling ...
NAMSA recently announced plans to acquire WuXi AppTec’s medical device testing operations in the U.S. As part of the ...
Fierce Pharma Asia—A $410M obesity debut; Another Roche ADC deal; Legend, BeiGene as buyout targets?
A new weight loss biotech launched with $410 million and three assets from China. Roche's Chugai penned a deal to develop ...
US passed Biosecure Act which would ban federal contracts with targeted firms and their business partners. Legislation ...
China’s WuXi Biologics said on Monday it will sell its vaccine facility in Ireland to US drug maker Merck & Co for about US$500 million, ahead of potential US legislation that would restrict ...
WuXi Biologics Cayman Inc. will sell a vaccine facility in Ireland to Merck & Co. for about $500 million as the Chinese company seeks to enhance its margins while continuing to navigate ...
WuXi Biologics agreed to sell an overseas vaccine facility to Merck & Co. for half a billion dollars, a move that could strengthen the company's cash flow and margins as it navigates global ...
Jan 6 (Reuters) - China's WuXi Biologics (2269.HK), opens new tab said on Monday it will sell its vaccine facility in Ireland to U.S. drugmaker Merck & Co (MRK.N), opens new tab for about $500 ...
Over 3,000 people are employed across the network. Merck and WuXi Vaccines are now entering a formal handover process, expected to conclude in the first half of 2025. Once complete, the facility ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback